ea0077p70 | Metabolism, Obesity and Diabetes | SFEBES2021
Allum Matthew
, Buckley Adam
, Lessan Nader
, Mohammed Nagi
, Suliman Mohamed
, Suliman Sara
, Elsheikh Mohgah
Background: The Glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide has shown improvements in glycaemia and other metabolic parameters for patients with type 2 diabetes (T2D) in clinical trials. Published real-world data are sparse and there are none from the Middle East where semaglutide became available in 2020.Method and Results: We retrospectively gathered data for 289 patients (median age 50 years (IQR 42-57), 36% female, 87% Emirati and 8...